Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ciprofol + alfentanil is a pharmacological combination used for procedural sedation and analgesia, particularly in the context of gastrointestinal endoscopies such as gastroscopy. Ciprofol (HSK3486) is a novel, short-acting intravenous anesthetic and a 2,6-disubstituted phenol derivative that functions as a potent agonist of the Gamma-aminobutyric acid type A (GABA_A) receptor. It was developed by Haisco Pharmaceutical Group to offer a similar clinical profile to propofol but with improved potency and a potentially better safety profile regarding injection pain and respiratory depression. Alfentanil is a potent, rapid-onset synthetic opioid that acts as a selective agonist of the mu-type opioid receptor, providing the necessary analgesia that hypnotics like ciprofol lack. When administered together, these agents provide a rapid onset of action, stable hemodynamics, and quick recovery times, making the combination suitable for brief diagnostic and therapeutic procedures.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ciprofol + alfentanil.